Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

What excipients are combined with ruxolitinib in apotex's medication?
Pramlintide acetate price?
Campath litigation germany?
Somatuline generic name?
Are there specific stretches to avoid while on lipitor?

Does vascepa affect warfarin's blood thinning ability?

See the DrugPatentWatch profile for vascepa

Short answer:
Vascepa (icosapent ethyl) is not known to alter warfarin’s metabolism or the INR directly, but it can add a small extra risk of bleeding when used together with warfarin or other anticoagulants.

What the evidence says

Source Key finding Practical take‑away
FDA label for Vascepa (2018) No clinically significant interaction with warfarin reported; however, the label notes that “omega‑3 fatty acids may increase bleeding risk when combined with warfarin or other anticoagulants.” Be vigilant for signs of bleeding, and consider routine INR checks.
American College of Cardiology/AHA Guidelines (2016) Discusses the benefit of omega‑3 fatty acids for cardiovascular risk reduction but does not list warfarin as a contraindication. No dose adjustment of warfarin is usually needed.
Clinical pharmacology reviews No major effect on warfarin’s pharmacokinetics (CYP2C9, VKORC1 pathways) has been documented. Monitoring of INR remains the safest approach.
Case reports (e.g., 2014 JACC) A few reports of increased bleeding episodes when omega‑3s were combined with warfarin. Rare but possible; monitor closely.

Practical steps if you’re taking both drugs

  1. Regular INR monitoring

    • Keep your INR checks at the frequency your prescriber recommends (often every 4–6 weeks once stable).
    • If you notice a sudden rise in INR or bleeding symptoms (easy bruising, nosebleeds, blood‑tinged stool/urine), contact your clinician right away.

  2. Watch for bleeding symptoms

    • Small bruises, prolonged bleeding from cuts, or any unusual bleeding should prompt a check of INR and a discussion with your provider.

  3. Avoid other bleeding‑risk drugs

    • NSAIDs, aspirin, and certain herbal supplements can compound the effect.
    • If you need a pain reliever, talk to your provider about safer options.

  4. Inform any healthcare professional

    • Be sure every doctor, dentist, or pharmacist knows you’re on both warfarin and Vascepa to avoid inadvertent drug interactions.

  5. Stay consistent with dosing

    • Do not skip warfarin doses, even if you’re taking Vascepa; warfarin’s anticoagulant effect depends on consistent daily intake.

Bottom line

  • Vascepa does not change warfarin’s metabolism or INR in a clinically meaningful way.
  • It may increase bleeding risk slightly, especially if you’re already on other anticoagulants or antiplatelet agents.
  • Monitoring (especially INR) and communication with your healthcare team are the best safeguards.

If you have any doubts or experience new bleeding symptoms, call your prescribing clinician or the emergency department—better to check than to risk serious bleeding complications.



Other Questions About Vascepa :

can yoogetheru take vascepa & potassium t What's the epa dosage in vascepa per capsule? What is the cost of vascepa online? Vascepa or chia seeds higher epa amount? How has vascepa's price changed recently? How should i document vascepa side effects for my doctor? Are specific drug interactions a concern with vascepa?

AI-Drug Label Prescribing Information Alignment Report

18
18%
Grade F

Poor

Not Aligned

Patient Risk: High

Summary

Four INR/warfarin-effect claims are not supported by the provided FDA label excerpts (which discuss bleeding risk and monitoring, not INR effects). One claim is only partially supported because labeling supports increased bleeding risk with concomitant anticoagulants (including warfarin) and monitoring, but does not substantiate the specific non-interaction etiologies listed.

Category Scores

Warnings
45
Poor
DrugInteractions
10
Poor

Accurate Statements

Warfarin (as a concomitant anticoagulant) is associated with a greater incidence of bleeding when used with VASCEPA, and patients receiving VASCEPA with concomitant anticoagulants/antiplatelet agents should be monitored for bleeding.
Supported by 5.3 Bleeding (greater incidence of bleeding in patients receiving concomitant antithrombotic medications, such as warfarin) and 7.1 Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents (monitor patients receiving VASCEPA and concomitant anticoagulants and/or antiplatelet agents for bleeding).

Unsupported Statements

Vascepa (icosapent ethyl) does not appear to have a clinically important effect on warfarin’s anticoagulation.
The provided label excerpts do not discuss warfarin anticoagulation effect or make a conclusion that VASCEPA has no clinically important effect on warfarin.
In a study of warfarin users who added icosapent ethyl, INR did not show a meaningful change attributable to Vascepa.
The provided label excerpts do not report INR outcomes or describe any warfarin+icosapent ethyl INR study results.
In a drug-interaction study, starting icosapent ethyl in participants taking warfarin and monitoring INR did not show a significant difference versus warfarin alone.
The provided label excerpts discuss bleeding risk/monitoring but provide no INR comparison or description of such a study.
The specific interaction signal for icosapent ethyl and warfarin is not one of a meaningful INR increase.
The provided label excerpts do not mention INR increases or characterize an interaction signal in INR terms.

Contradictions

Important Omissions

If discussing anticoagulation impact, the label excerpts provided support monitoring for bleeding with concomitant anticoagulants/antiplatelet agents rather than making INR-effect conclusions; the response omits this labeling-supported guidance in its INR-focused framing.
Importance: Moderate

Safety Assessment

Potential Patient Risk: High
Overconfident INR/warfarin-effect assertions not supported by the provided label excerpts could undermine appropriate monitoring. The label provided emphasizes increased bleeding risk and monitoring with concomitant anticoagulants/antiplatelet agents.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk High

Recommendation

Not Aligned

Primary Issue
Multiple claims assert INR/warfarin anticoagulation effects (no clinically important effect, no meaningful INR change, no significant difference vs warfarin alone, no INR increase signal) that are not supported by the provided FDA label excerpts.

Suggested Improvement
Rephrase to align with provided label excerpts: state that VASCEPA is associated with an increased risk of bleeding and that patients receiving VASCEPA with concomitant anticoagulants and/or antiplatelet agents should be monitored for bleeding; avoid INR-specific conclusions unless supported by explicit label INR data.

Drug Brand Mention Assessment

Branding Score
59
Visibility
63
Mentioned
Ranking
#1
Sentiment
41
Recommendation Status
mentioned only
Brand Perception
Best Known For

“no clinically important change in warfarin effect on INR”

Core Claims
  • “Vascepa does not appear to have a clinically important effect on warfarin’s anticoagulation.”
  • In a study, INR “did not show a meaningful change attributable to Vascepa.”
  • Results showed “no substantial impact on warfarin effect.”
  • “The specific interaction signal for icosapent ethyl and warfarin… is not one of a meaningful INR increase.”
  • Evidence “points to no clinically important change in warfarin effect on INR.”
Differentiators
  • No meaningful change in INR when icosapent ethyl is added to warfarin
  • Interaction signal “not… a meaningful INR increase”
Pricing Perception: Not Mentioned